Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod versus ALA photodynamic therapy for actinic keratoses in organ transplant recipients
2012-000263-24Phase 4Terminated
- Sponsor
- Medical University of Vienna
- Start
- May 2012
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imiquimod and 5-aminolevulinic acid in actinic keratosis (AK) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Clinical complete remission rate. Started May 2012; status: terminated.
02
Drugs
imiquimod5-aminolevulinic acid
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on 2012-000263-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000263-24.